CAS No.: 367514-88-3
Product introduction:Lurasidone HCl (also known as Lurasidone hydrochloride, with research code SM-13496) is an atypical antipsychotic agent first discovered and developed by Sumitomo Dainippon Pharma (now Sumitomo Pharma). The compound is the hydrochloride salt form of Lurasidone, a potent antagonist at dopamine D2 and serotonin 5‑HT2A receptors, which are believed to mediate its efficacy in treating schizophrenia and bipolar depression. Notably, Lurasidone also demonstrates high affinity for 5‑HT7 and 5‑HT1A receptors, a profile distinct from many other atypical antipsychotics. The drug received its first U.S. FDA approval for schizophrenia in 2010, later gaining approvals for bipolar depression as both monotherapy and adjunctive therapy with mood stabilizers such as lithium or valproate.
CAS No.:367514-88-3
Lurasidone HCl is a white to off‑white crystalline powder. Its molecular formula is C₂₈H₃₇ClN₄O₂S with a molecular weight of approximately 529.14 g/mol. The compound is practically insoluble in water but is soluble in organic solvents such as DMSO. It is recommended to store the powder under inert gas in a refrigerator (2‑8°C), protected from light and moisture.
Core Functions:
Active pharmaceutical ingredient (API) in oral tablet formulations (e.g., Latuda®, 20‑120 mg) for the treatment of schizophrenia (adults and adolescents aged 13‑17) and bipolar I depression (as monotherapy or adjunctive therapy with lithium or valproate)
Research use in neuropharmacological studies focusing on dopamine D2 and serotonin 5‑HT2A/5‑HT7 receptor antagonism
Reference standard for analytical method development and quality control in pharmaceutical testing
Ongoing investigation in pediatric populations and other mood disorder indications
Contact: Tony
Phone: 008618700976396
E-mail: sales@fulecare.com
Whatsapp:008618700976396
Add: Zhang Ba 6 Road,Hi tech zone,Xi'an Shaanxi Province,China
